GlassScriptPhysician profile
Ashish Arshanapalli
NPI 1639563505
$5,709.25
in general payments reported to CMS, 2019-2025
27 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $82.56 · 2021: $497 · 2022: $1,034 · 2023: $1,020 · 2024: $1,607 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.65 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,077.20 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $665.80 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $526.26 | 2021-2025 | Adbry |
| Ucb, INC. | $350.70 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $341.55 | 2020-2024 | Rinvoq |
| Sun Pharmaceutical Industries INC. | $340.47 | 2021-2025 | Odomzo, Blu-U |
| Incyte Corporation | $319.28 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $294.01 | 2023-2025 | |
| Janssen Biotech, INC. | $283.74 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $273.01 | 2022-2024 | Vtama |
| Lilly USA, LLC | $177.03 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $166.33 | 2024-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $156.80 | 2022-2025 | |
| Galderma Laboratories, L.P. | $129.72 | 2020-2025 | |
| Biotissue Holdings INC. | $99.99 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.38 | 2022-2024 | Spevigo |
| Pfizer INC. | $71.38 | 2021-2023 | |
| Almirall LLC | $67.98 | 2023-2024 | Klisyri |
| Organon LLC | $36.28 | 2025 | Vtama |
| Journey Medical Corporation | $35.35 | 2020-2022 | |
| Kerecis Limited | $33.79 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Fresenius Kabi USA, LLC | $22.44 | 2023 | Idacio |
| Amgen INC. | $18.70 | 2025 | Otezla |
| Paratek Pharmaceuticals, INC. | $16.24 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.00 | 2025 | Cabtreo |
| Biofrontera INC. | $10.49 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Arshanapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.